Asco 2019 – the case for Nektar sweetens, slightly
Longer-term data bolster Nektar Therapeutics’ bempegaldesleukin, but things haven’t changed that much since its last disappointment.
Asco 2019 – Seattle sees an Adcetris follow-up on the horizon at last
A mid-stage study of enfortumab illustrates the relevance of nectin-4 in urothelial bladder cancer, and is hailed by experts as registrational.
Asco 2019 – Polo reveals an overall survival hole
The keenly awaited study of Lynparza in pancreatic cancer maintenance fails to show much beyond its headline primary endpoint of progression-free survival.
Asco 2019 – top marks for effort to Merck & Co in gastric cancer
A first-line Keytruda study is nominally positive, but numerous questions remain before approval can be assured.
Upcoming events – Anaptysbio and Retrophin await big readouts
Anaptysbio’s etokimab needs to beat Dupixent, while Retrophin takes aims at an underserved rare disease.
Go or no go? Merck, Regeneron and Alexion await US expansion
Approvals for new uses of old drugs should far outweigh nods for novel projects in June.
Keytruda looks to secure a June double play
Merck & Co faces two US FDA decisions in June, and neither is an obvious guarantee of success.
Upcoming events – key tests approach for Biogen and Kalvista
Biogen needs a win with its Tecfidera follow-on, while Kalvista hopes to make HAE where Biocryst failed.
Biomarin hopes long-term valrox data can stem the bleeding
Expectations are low for a three-year update on the group’s haemophilia A gene therapy, and Biomarin’s rivals could capitalise on any slip-up.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.